IHS Chemical Week

Regions :: Western Europe :: Switzerland

Lonza signs agreement with Index Ventures for development and manufacture of biologics

12:04 AM MST | January 9, 2014 | Deepti Ramesh

Lonza and Index Ventures, a leading venture capital investment firm, have signed an exclusive five-year agreement for process development and cGMP production for all biological products in the portfolio of companies where Index Ventures is the major investor. Additional development and manufacturing projects will be added to the product list over the course of the agreement as future investments are made by Index Ventures, Lonza...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Not an IHS Chemical Week member yet?

Here's why you should be:

  • 31 issues of Chemical Week magazine in print or digital format
  • Critical daily news and analysis on chemweek.com
  • Free mobile edition 
  • 20+ years of online archives
  • Topical e-newsletters that capture the most impactful events
  • Special issues with a regional or company focus
  • Global Outlook issue

Subscribe now

100% Satisfaction Guarantee
If at any time you are not completely satisfied with IHS Chemical Week, simply notify us and we'll refund the balance of your paid subscription - no problem.

Learn more about group subscriptions and site licenses.


contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2015 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa